The emerging role of adipocytokines as inflammatory mediators in inflammatory bowel disease

被引:59
|
作者
Karmiris, K [1 ]
Koutroubakis, IE [1 ]
Kouroumalis, EA [1 ]
机构
[1] Univ Hosp Heraklion, Dept Gastroenterol, Iraklion 71110, Greece
关键词
adipocytokines; adiponectin; Crohn's disease; ghrelin; leptin; resistin; ulcerative colitis;
D O I
10.1097/01.mib.0000178915.54264.8f
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Anorexia, malnutrition, altered body composition and development of mesenteric obesity are well known features of inflammatory bowel disease (IBD). Recent data suggest that dysregulation of protein secretion by white adipose tissue is involved in these manifestations of patients with IBD. Adipocytes are recently recognized as endocrine cells that secrete a variety of bioactive substances known as adipocytokines. There is evidence that adipocytokines are involved in inflammatory and metabolic pathways in human beings. Overexpression of adipocytokines such as leptin, adiponectin and resistin in mesenteric adipose tissue of operated patients with Crohn's disease has recently been reported, suggesting that mesenteric adipocytes in IBD may act as immunoregulating cells. Therefore, it could be suggested that adipocytokines play an important role in the disease pathogenesis. Moreover, modulators of mesenteric adipose function have been suggested as potential therapeutic drugs in IBD. In this review, the importance of white adipose tissue function and adipocytokines, is discussed with respect to IBD.
引用
收藏
页码:847 / 855
页数:9
相关论文
共 50 条
  • [31] INFLAMMATORY MEDIATORS IN INFLAMMATORY BOWEL-DISEASE - CLUES FOR DESIGNER THERAPY
    WALLACE, JL
    CANADIAN JOURNAL OF GASTROENTEROLOGY, 1993, 7 (02): : 121 - 126
  • [32] INFLAMMATORY MEDIATORS IN CHRONIC INFLAMMATORY BOWEL DISEASES
    GROSS, V
    ANDUS, T
    LESER, HG
    ROTH, M
    SCHOLMERICH, J
    KLINISCHE WOCHENSCHRIFT, 1991, 69 (21-23): : 981 - 987
  • [33] INVESTIGATING THE ROLE OF SOLUBLE MEDIATORS IN INFLAMMATORY BOWEL-DISEASE USING COCULTURE
    WARDLE, TD
    TURNBERG, LA
    GUT, 1990, 31 (05) : A593 - A593
  • [34] Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease
    McCormack, Matthew D.
    Wahedna, Natasha A.
    Aldulaimi, David
    Hawker, Peter
    WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (12)
  • [35] Beyond Gene Discovery in Inflammatory Bowel Disease: The Emerging Role of Epigenetics
    Ventham, Nicholas T.
    Kennedy, Nicholas A.
    Nimmo, Elaine R.
    Satsangi, Jack
    GASTROENTEROLOGY, 2013, 145 (02) : 293 - 308
  • [36] Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients
    Hala Najeeb
    Farah Yasmin
    Salim Surani
    World Journal of Clinical Cases, 2022, (14) : 4327 - 4333
  • [37] Emerging Role of Dendritic Cell Intervention in the Treatment of Inflammatory Bowel Disease
    Sun, Donglei
    Li, Chenyang
    Chen, Shuang
    Zhang, Xiaolan
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [38] Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease
    Matthew D McCormack
    Natasha A Wahedna
    David Aldulaimi
    Peter Hawker
    World Journal of Clinical Cases, 2023, (12) : 2621 - 2630
  • [39] The emerging role of the gut microbiota and its application in inflammatory bowel disease
    Wang, Xiu
    Peng, Jianhua
    Cai, Peipei
    Xia, Yuxuan
    Yi, Chengxue
    Shang, Anquan
    Akanyibah, Francis Atim
    Mao, Fei
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 179
  • [40] Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients
    Najeeb, Hala
    Yasmin, Farah
    Surani, Salim
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (14) : 4327 - 4333